Tom Goodrich

The Architect of Three Acts

In venture capital, longevity is rare and pattern recognition is everything. Tom Goodrich has been at this since 1991 - when the World Wide Web had just gone public and "startup" was not yet a personality type. What he built wasn't a fund. It was a lineage: Duff Ackerman & Goodrich begat DAG Ventures, which begat Corner Ventures. Each one a deliberate evolution, not a reset.

Today Goodrich serves as Co-Founder and General Partner at Corner Ventures, the Palo Alto-based firm he launched in late 2018 alongside longtime collaborator John Cadeddu and Marvin Tien. Corner was spun directly out of DAG Ventures - a $300M fund that had backed nearly 180 companies over 14 years - and it carries that track record like a blueprint. From its offices in Palo Alto, New York, Tel Aviv, and Tokyo, Corner has assembled a portfolio of 89+ companies, four unicorns, eight IPOs, and forty acquisitions.

The Biotech Caller

Inside Corner Ventures, Goodrich leads the biotech portfolio - a focused, high-conviction corner of the fund where the bets are longer and the exits, when they come, tend to be headline-worthy. His record there is hard to argue with.

Armo Biosciences, which he backed, was acquired by Eli Lilly. Arresto Biosciences went to Gilead Sciences. Atara Biotherapeutics trades on NASDAQ under the ticker ATRA. Current positions include Dantari Pharmaceuticals, Latigo Biotherapeutics, and Oncovalent Therapeutics - each at earlier stages, each following the same pattern of backing science before the market knows what to do with it.

This is not a generalist dipping a toe into life sciences. Goodrich built this expertise over decades, starting with investments at DAG Ventures that included Bloom Energy, Fortify Software (acquired by Hewlett Packard), Oakley Networks (acquired by Raytheon), and Matrix Memory (acquired by SanDisk). Before biotech became a venture category, he was watching biology and technology converge from inside the deal flow.

Before the Funds

The career that preceded Duff Ackerman & Goodrich is not the usual résumé. After earning his A.B. from Dartmouth and his MBA from Stanford Graduate School of Business, Goodrich moved through a series of institutions that were less about building wealth and more about understanding how capital actually moves. He worked with the Stanford Research Institute. He served as an independent consultant to the office of the Chairman of Bank of America. He co-founded Dimensional Corporate Finance, Inc. - a specialty finance firm backed by Xerox - and ran it as Vice President.

Then came Bechtel Investments, where as a principal he oversaw management buyouts and special situation investments in mid-size growth companies. Private equity fundamentals learned in environments that don't reward theory. By the time he co-founded Duff Ackerman & Goodrich in 1991 with David Duff and Ron Ackerman, he had already watched capital flow through research labs, boardrooms, and balance sheets.

The DAG Era

DAG Ventures launched in 2004, spun out of Duff Ackerman & Goodrich with a different thesis: mid-stage venture, working alongside entrepreneurs and select early-stage VCs who needed a bridge between seed conviction and growth capital. The portfolio that followed is a Silicon Valley reading list: Yelp, Wix, Wealthfront, Eventbrite, Grubhub, Nextdoor, Glassdoor, FireEye, and Ambarella. Names that went public, got acquired, or became synonymous with their category.

Goodrich co-led that firm with Cadeddu for fourteen years. The fund grew to $300M. The track record compounded. And in late 2018, when Cadeddu, Tien, and Goodrich decided to spin out and build something new, they didn't start from scratch - they started from proof.

Global Architecture

Corner Ventures is not a Silicon Valley firm that occasionally takes meetings abroad. The offices in Tel Aviv and Tokyo are structural, not symbolic. Israel's startup density - particularly in deep tech and cybersecurity - and Japan's combination of capital, corporate relationships, and underserved early-stage market make both locations productive. Tracxn data shows 10 of Corner's portfolio companies are Israel-based, reflecting a real deployment thesis rather than flag-planting.

The Israel connection traces back to DAG's investing history, where the network of founders and co-investors built over a decade gave Corner real access at formation. The Tokyo office extends the same logic eastward - a team with relationship capital in a market where deal flow depends entirely on trust built over time.

The Institutional Instinct

Goodrich's career has a recurring pattern: find an institution others aren't paying attention to, understand how it works, and then build something alongside it. Stanford Research Institute before venture was a thing. Bank of America's chairman's office before fintech was a category. Xerox before tech incumbents learned to invest in startups. Bechtel before private equity had been democratized.

That instinct - for the institution ahead of the curve - is what eventually pointed toward biotech. When Goodrich was making those early life science bets at DAG, genome sequencing was still expensive, mRNA was theoretical, and immunotherapy was an academic curiosity. He saw Armo Biosciences before Lilly saw it. He saw Arresto before Gilead.

The pattern is not luck. It's a methodology built over 35 years of showing up early, understanding the science, building relationships with researchers and clinicians, and having the patience to wait. In a world of quarterly updates and founder Twitter threads, Goodrich represents a different velocity - slower, deeper, and built to last.